On February 5, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA) therapeutic platform reported that it will give a webcast presentation at the BIO CEO and Investor Conference(Press release, RXi Pharmaceuticals, FEB 5, 2018, View Source [SID1234523727]). RXi’s President and CEO, Dr. Geert Cauwenbergh, will highlight the Company’s therapeutic platform and its business strategy to advance the development of a new class of cancer therapeutics, using adoptive cell transfer (ACT).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Developing Self-Delivering RNAi (sd-rxRNA) for Immuno-oncology
Track and location: Oncology, Room: Odets
Date and Time: Monday, February 12, 2018, 2:15 pm ET
Presenter: Dr. Geert Cauwenbergh, President and CEO
Now in its 20th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference will take place February 12-13, 2018 at the New York Marriott Marquis in New York City.
The link for the webcast may be found on the Company’s website under the "Investors – Events and Presentations" section at www.rxipharma.com.